MedTrace Logo

Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients

NCT04218435 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-02-01

No results posted yet for this study

Summary

The two primary goals of it's management are preventing further disease progression(mortality,hospitalizations and deterioration of left ventricular function)and alleviating patient suffering

Conditions

  • Heart Failure NYHA Class IV
  • Heart Failure NYHA Class II

Interventions

DRUG

Sacubitril / Valsartan Oral Tablet

Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB.

Sponsors & Collaborators

  • Clinision

    lead OTHER

Principal Investigators

  • Shahryar Shiekh · Doctors hospital and Medical center, Lahore

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-10-25
Completion
2020-12-30
FDA Drug
Yes

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04218435 on ClinicalTrials.gov